{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-056294","form_type":"8-K","ticker":"SILO","cik":"0001514183","company_name":"Silo Pharma, Inc.","filed_at":"2022-09-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.986323+00:00","generated_at":"2026-06-23T09:23:15.390659+00:00","sec_items":["5.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Silo Pharma implements 1-for-50 reverse stock split in preparation for Nasdaq uplisting","bullets":["Reverse split at ratio of 1-for-50 effective 4:01 p.m. ET on September 14, 2022.","Common stock will trade on OTC Markets under temporary symbol 'SILOD' until Nasdaq listing.","Post-split shares outstanding approximately 1,987,906; fractional shares rounded up.","Stockholders approved reverse split range at special meeting on March 11, 2022.","Company has filed Nasdaq listing application and believes it meets all requirements except minimum share price."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-056294","json":"https://secwatch.observer/filing/0001213900-22-056294.json","markdown":"https://secwatch.observer/filing/0001213900-22-056294.md","text":"https://secwatch.observer/filing/0001213900-22-056294.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1514183/000121390022056294/0001213900-22-056294-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1514183/000121390022056294/ea165863-8k_silopharma.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T09:23:15.390659+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}